Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle

Francesca Pretto; Carmen Ghilardi; Michele Moschetta; Andrea Bassi; Alessandra Rovida; Valentina Scarlato; Laura Talamini; Fabio Fiordaliso; Cinzia Bisighini; Giovanna Damia; Maria Rosa Bani; Rosanna Piccirillo; Raffaella Giavazzi

doi:10.18632/oncotarget.9971

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle

Francesca Pretto, Carmen Ghilardi, Michele Moschetta, Andrea Bassi, Alessandra Rovida, Valentina Scarlato, Laura Talamini, Fabio Fiordaliso, Cinzia Bisighini, Giovanna Damia, Maria Rosa Bani, Rosanna Piccirillo and Raffaella Giavazzi _

PDF | How to cite

Oncotarget. 2016; 7:38973. https://doi.org/10.18632/oncotarget.9971

Metrics: PDF 3213 views | ?

Present: Due to an error made during the manuscript revision process, a notice designating Drs. Rosanna Piccirillo and Raffaella Giavazzi as joint last authors has been omitted.

Corrected: Correct author list is provided below. Authors sincerely apologize for this oversight.

Original article: Oncotarget. 2015; 6(5): 3043-54. DOI: 10.18632/oncotarget.2812

Francesca Pretto^1,4,*, Carmen Ghilardi^1,*, Michele Moschetta¹, Andrea Bassi², Alessandra Rovida¹, Valentina Scarlato¹, Laura Talamini¹, Fabio Fiordaliso³, Cinzia Bisighini³, Giovanna Damia¹, Maria Rosa Bani¹, Rosanna Piccirillo^1,** and Raffaella Giavazzi^1,**

¹ Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”, 20156 Milan, Italy
² Department of Phisics, Politecnico di Milano, 20133 Milan, Italy³ Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”, 20156 Milan, Italy 4 Present address: Philochem AG, 8112 Otelfingen, Switzerland
^*These authors have contributed equally to this work
^** Joint last authors

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9971

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle